Article (Scientific journals)
Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction - PROMISE.
Schleich, FLorence; Moermans, Catherine; Seidel, Laurence et al.
2023In ERJ Open Research, 9 (6)
Peer Reviewed verified by ORBi
 

Files


Full Text
SCHLEICH 2023_ Benralizumab in severe eosinophilic asthma_ERJ Open_ppediteur.pdf
Author postprint (681.58 kB) Creative Commons License - Attribution, Non-Commercial
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] BACKGROUND: Randomised controlled trials have shown that benralizumab, an anti-interleukin-5 receptor monoclonal antibody, reduces exacerbations and oral corticosteroid dose and improves asthma control and lung function in severe eosinophilic asthma. The aim of this study was to confirm results of randomised controlled trials in real life in a population of 73 patients with severe eosinophilic asthma treated with benralizumab for at least 12 months. METHODS: Patients underwent careful monitoring of asthma exacerbations, exhaled nitric oxide fraction, lung function, asthma control and quality of life questionnaire responses and sputum induction, and gave a blood sample at baseline, after 6 months and then every year. RESULTS: We found significant reductions in exacerbations (by 92%, p<0.0001) and oral corticosteroid dose (by 83%, p<0.001) after 6 months that were maintained over time, with 78% of patients able to stop oral corticosteroid therapy. Patients improved their Asthma Control Test (ACT) score (from 11.7±5.1 to 16.9±5.35, p<0.0001), Asthma Control Questionnaire (ACQ) score (from 2.88±1.26 to 1.77±1.32, p<0.0001) and Asthma Quality of Life Questionnaire score (+1.04, p<0.0001) at 6 months and this was maintained during follow-up. Only 35% and 43% of patients reached asthma control according to an ACT score ≥20 and ACQ score <1.5, respectively. We observed stable post-bronchodilation lung function over time and a significant reduction in sputum eosinophil count, with 85% of patients exhibiting sputum eosinophil counts <3% after 6 months (p<0.01) with no effect on exhaled nitric oxide fraction. CONCLUSION: In our real-life study, we confirm the results published in randomised controlled trials showing a sharp reduction in exacerbations and oral corticosteroid therapy, an improvement in asthma control and quality of life, and a dramatic reduction in sputum eosinophil count.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Schleich, FLorence  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Moermans, Catherine  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Seidel, Laurence  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
Kempeneers, Céline  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie
Louis, Gilles  ;  Université de Liège - ULiège > Santé publique : de la Biostatistique à la Promotion de la Santé
ROGISTER, Florence  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'ORL, d'audiophonologie et de chir. cervico-faciale
Tombu, Sophie ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'ORL, d'audiophonologie et de chir. cervico-faciale
Pottier, Laurence ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'ORL, d'audiophonologie et de chir. cervico-faciale
Poirrier, Anne-Lise  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'ORL, d'audiophonologie et de chir. cervico-faciale
ZIANT, Stéphanie ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Henket, Monique ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
SANCHEZ, Carole ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
PAULUS, Virginie ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
GUISSARD, Françoise ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Donneau, Anne-Françoise ;  Université de Liège - ULiège > Département des sciences de la santé publique
Louis, Renaud ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
More authors (6 more) Less
Language :
English
Title :
Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction - PROMISE.
Publication date :
November 2023
Journal title :
ERJ Open Research
eISSN :
2312-0541
Publisher :
European Respiratory Society, Sheffield, Gb
Volume :
9
Issue :
6
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright ©The authors 2023.
Available on ORBi :
since 08 January 2024

Statistics


Number of views
23 (3 by ULiège)
Number of downloads
5 (1 by ULiège)

Scopus citations®
 
0
Scopus citations®
without self-citations
0

Bibliography


Similar publications



Contact ORBi